ReviewJournal of materials science. Materials in medicine2025
Fucoidan in cancer therapy: from biomedical application to medicinal chemistry approach.
Review in Journal of materials science. Materials in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Fucoidans: a new frontier in brown seaweed research and biotechnology.Cell surface (Amsterdam, Netherlands) · 2026Review
- Fucoidan-Based Combination Strategies in Cancer Therapy: Biological Basis, Current Evidence, and Future Perspectives.International journal of molecular sciences · 2026Review
- Fucoidans as multifunctional marine polysaccharide platforms: From nutritional supplements to advanced drug delivery for cancer therapy.International journal of pharmaceutics: X · 2026Review
- Algae-Derived Bioactive Compounds as Platforms for Translational Biotechnology and Health Applications.Biotech (Basel (Switzerland)) · 2026Review
- Bioactive Natural Compounds in Triple-Negative Breast Cancer: Molecular Targets and Therapeutic Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Marine Algae Hydrogels as Emerging Biomaterials for Medicine.Gels (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Biomaterials based on carbohydrate polymers, particularly modified polysaccharides, are gaining attention for cancer treatment due to their diverse properties and performance in clinical applications. While research on polysaccharides like chitosan and alginate is abundant, studies on chemically functionalized derivatives are limited. These derivatives, such as fucoidan, sulfated polysaccharides from brown seaweeds, offer minimal side effects and suitable drug release profiles. Fucoidan exhibits various biological activities, including anticancer, anti-inflammatory, and immunomodulatory effects, making it a promising candidate for cancer diagnosis and therapy. This review is the first to comprehensively explore the applications of fucoidan in combating cancer, focusing on its ability to inhibit tumor growth, induce cell death, and modify the tumor microenvironment. Additionally, the review discusses nanostructured chemically modified fucoidan-based biomaterials, which show potential for hydrogel engineering and enhanced drug delivery systems. These advancements highlight the significance of chemical modifications and mechanistic insights into targeted drug delivery and controlled release rates. Incorporating fucoidan into nanocarriers improves its biodegradability, biocompatibility, and structural stability, facilitating surface modifications that enhance targeting efficiency and therapeutic efficacy. This integrated approach of combining fucoidan's natural properties with nanotechnology presents innovative therapeutic opportunities for cancer treatment, aiming to improve patient outcomes while minimizing side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.